Nu­mero quat­tro: Im­munol­o­gy ex­perts at deal-fo­cused IFM line up $55.5M for the next leg of their drug ex­plo­ration jour­ney

It’s pipeline prim­ing time at IFM Ther­a­peu­tics. And they have the mon­ey to get the job done.

The im­munol­o­gy ex­perts at the dis­cov­ery out­fit have lined up $55.5 mil­lion in new ven­ture back­ing from an ex­pand­ed syn­di­cate — still in­clud­ing their big be­liev­ers at At­las. And it’s not hard to fig­ure out the mo­ti­va­tion.

Gary Glick, who’s mov­ing from CEO to ex­ec­u­tive chair­man on this round, and his team have lined up a slate of deals for their ear­ly-stage work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER